Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Thejeel B, Geannette CS, Roytman M, Pisapia DJ, Chazen JL, Jawetz ST. Patterns of Intrathecal Ossification in Arachnoiditis Ossificans: A Retrospective Case Series. AJNR Am J Neuroradiol. 2023;44(2):228-234.

Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, et al. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol. 2023;83(6):486-494.

Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, et al. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023;7:e2200334.

Baillargeon D, Greenblatt M, Côté M, Nadeau M, Couture C-, Hould F-, et al. Prevalence of Helicobacter pylori Infection in Bariatric Surgery Patients. Obes Surg. 2023;33(7):2132-2138.

Zhang T, Li S, Tan YA, Na JH, Chen Z, Damle P, et al. Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis. bioRxiv. 2023.

Callum J, Bégin P, Jamula E, Liu Y, Kron AT, Auclair M-, et al. Lessons learned from the CONCOR-1 trial. Transfus Med. 2023;33(1):21-25.

Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, et al. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Lancet Haematol. 2023;10(8):e624-e632.

Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis GB, Mandell M, et al. Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway. NPJ Precis Oncol. 2023;7(1):9.

2022

Fowler FC, Chen B-, Zolnerowich N, Wu W, Pavani R, Paiano J, et al. DNA-PK promotes DNA end resection at DNA double strand breaks in G0 cells. Elife. 2022;11.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, et al. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Front Endocrinol (Lausanne). 2022;13:1006101.